ANGPTL3、Myostatin对妊娠期糖尿病新生儿低血糖的预测价值

摘要/Abstract

摘要： 目的探讨血管生成素样蛋白3（ANGPTL3）、血清肌肉生长抑素（Myostatin）对妊娠期糖尿病新生儿低血糖的预测价值。方法选取四川省雅安市中医医院2018年1月—2022年10月收治的80例妊娠期糖尿病患者进行回顾性分析,将其设为观察组,另选取同期来四川省雅安市中医医院体检的80名健康孕妇志愿者作为对照组,对比两组孕妇ANGPTL3、Myostatin表达水平,分析ANGPTL3、Myostatin与妊娠期糖尿病的相关性。随后收集80例妊娠期糖尿病患者的产后资料,排除3例早产和1例死胎,将剩余的76例顺利娩出胎儿的妊娠期糖尿病患者,依照新生儿是否出现低血糖进行分组,将新生儿出现低血糖的50例患者分为新生儿低血糖组,将26例未出现新生儿低血糖的患者分为非新生儿低血糖组,对比两组患者孕期ANGPTL3、Myostatin表达水平及临床一般情况,采用Logistic回归分析分析ANGPTL3、Myostatin对妊娠期糖尿病新生儿低血糖的预测价值。结果观察组孕妇孕期ANGPTL3、Myostatin水平明显高于对照组,差异有统计学意义（P<0.05）;Pearson相关分析结果表明：ANGPTL3、Myostatin与妊娠期糖尿病严重程度呈正相关（P<0.05）。新生儿低血糖组与非新生儿低血糖组的妊娠期糖尿病患者自然流产史情况、年龄、孕前BMI、分娩孕周对比差异无统计学意义（P>0.05）,糖尿病家族史、空腹血糖、餐后1 h血糖、餐后2 h血糖、ANGPTL3、Myostatin水平对比差异无统计学意义（P<0.05）;Logistic回归分析结果表明,ANGPTL3、Myostatin为妊娠期糖尿病新生儿低血糖的独立危险因素（P<0.05）。结论 ANGPTL3、Myostatin与妊娠期糖尿病的发生与发展具有一定相关性,另外通过妊娠期糖尿病患者孕期ANGPTL3、Myostatin水平可预测新生儿低血糖的发生情况,因此需在生产时采取相关措施及时预防新生儿低血糖现象,或对此类新生儿娩出后及时补充葡萄糖。

关键词: 血管生成素样蛋白3, 血清肌肉生长抑素, 妊娠期糖尿病, 新生儿低血糖

Abstract: Objective To explore the predictive value of angiopoietin like protein 3 (ANGPTL3) and serum myostatin (Myostatin) on hypoglycemia in diabetes neonates during pregnancy. Methods 80 patients with gestational diabetes admitted to Ya'an Traditional Chinese Medicine Hospital in Sichuan Province from January 2018 to October 2022 were selected for retrospective analysis, and they were divided into the observation group. In addition, 80 healthy pregnant women volunteers who came to Ya'an Traditional Chinese Medicine Hospital in Sichuan Province for physical examination in the same period were selected as the control group. The expression levels of ANGPTL3 and Myostatin in the two groups of pregnant women were compared, and the correlation between ANGPTL3, Myostatin and gestational diabetes was analyzed. Then we collected the postpartum data of 80 cases of pregnancy diabetes patients, excluded 3 cases of premature delivery and 1 case of stillbirth, and divided the remaining 76 cases of pregnancy diabetes patients who successfully delivered the fetus into two groups according to whether the newborn had hypoglycemia, divided 50 cases of neonatal hypoglycemia into neonatal hypoglycemia group, and divided 26 cases of patients who did not have neonatal hypoglycemia into non neonatal hypoglycemia group, and compared the two groups of patients with ANGPTL3. The expression level of Myostatin and the general clinical situation were analyzed by Logistic regression analysis. Results The levels of ANGPTL3 and Myostatin in the observation group during pregnancy were significantly higher than those in the control group (P<0.05); Pearson correlation analysis showed that ANGPTL3 and Myostatin were positively correlated with the severity of gestational diabetes (P<0.05); There was no significant difference between the neonatal hypoglycemia group and the non neonatal hypoglycemia group in the history of spontaneous abortion, age, BMI before pregnancy, and gestational weeks of delivery of diabetes patients during pregnancy (P>0.05), but there were significant differences in the family history of diabetes, empty blood glucose, blood glucose 1 hour after meal, blood glucose 2 hours after meal, ANGPTL3, and Myostatin levels (P<0.05); Logistic regression analysis showed that ANGPTL3 and Myostatin were independent risk factors for hypoglycemia in diabetes neonates during pregnancy (P<0.05). Conclusion ANGPTL3 and Myostatin have a certain correlation with the occurrence and development of diabetes in pregnancy. In addition, the level of ANGPTL3 and Myostatin in pregnancy can predict the occurrence of neonatal hypoglycemia. Therefore, it is necessary to take relevant measures to prevent neonatal hypoglycemia in time during production, or to supplement glucose in time after delivery of such newborns.

Key words: angiopoietin like protein 3, serum muscle somatostatin, gestational diabetes, neonatal hypoglycemia

中图分类号:

R714

冷在华. ANGPTL3、Myostatin对妊娠期糖尿病新生儿低血糖的预测价值[J]. 中华养生保健, 2023, 41(11): 54-57.

LENG Zai-hua. Predictive Value of ANGPTL3 and Myostatin on Hypoglycemia in Neonates with Gestational Diabetes[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(11): 54-57.

参考文献

[1] RASMUSSEN L, POULSEN CW, KAMPMANN U, et al.Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus[J]. Nutrients, 2020,12(10):3050.
[2] HOMAYOUNI A, BAGHERI N, MOHAMMAD-ALIZADEH-CHARANDABI S, et al. Prevention of Gestational Diabetes Mellitus (GDM) and Probiotics: Mechanism of Action: A Review[J]. Curr Diabetes Rev,2020,16(6):538-545.
[3] 张纹,程湘玮,王培红,等.新生儿低血糖预防与管理策略的构建[J].中国护理管理,2020,20(11):1694-1699.
[4] 张晓义,邱春霞,王尼萍.血清肌肉生长抑素血管生成素样蛋白3表达与妊娠期糖尿病的相关性[J].中国妇幼保健,2022,37(13):2374-2377.
[5] 魏小辉,王育璠.2015年国际妇产科联盟(FIGO)妊娠期糖尿病诊疗指南解读[J].中华内分泌代谢杂志,2016,32(11):895-899.
[6] 邵天伟,唐仕芳,陈龙,等.昆士兰临床指南:新生儿低血糖(2019版)解读[J].重庆医学,2021,50(24):4146-4149.
[7] 刘庆,蔡雯,张瑞晴,等.妊娠期糖尿病与口服葡萄糖耐量试验血糖正常孕妇胰岛素释放试验及血脂相关性研究[J].实用妇产科杂志,2020,36(5):368-372.
[8] 王焕焕,程湘玮,王培红,等.妊娠期糖尿病产妇分娩新生儿低血糖管理的最佳证据总结[J].护理学报,2020,27(3):31-36.
[9] 朱小蕾. 妊娠早中期糖化血红蛋白水平与妊娠结局的相关性分析[J].实用医药杂志,2020,37(8):701-704.
[10] BOIDO M, BUTENKO O, FILIPPO C, et al.A new protein curbs the hypertrophic effect of myostatin inhibition, adding remarkable endurance to motor performance in mice[J]. PLoS ONE,2020,15(3):e0228653.
[11] 冯斌,张南南,施毕旻.2型糖尿病合并亚临床动脉粥样硬化患者血清ANGPTL2水平变化及其意义[J].山东医药,2020,60(36):77-79.
[12] 于文慧,张彤,徐恒.参芪活血汤对2型糖尿病下肢血管病变患者症状及血清Vaspin,ANGPTL4水平的影响[J].中国临床研究,2022,35(7):927-931.
[13] 秦雯,陈泰文,郑海平,等.合并与未合并糖尿病的胰腺癌患者血管生成素样蛋白2在血清中的表达及其与预后的关系[J].临床肝胆病杂志, 2021,37(6):1398-1403.
[14] 孙雪梅,王锦栋,冯云梅.妊娠期糖尿病患者血清ANGPTL2和ANGPTL4水平与胰岛素抵抗的相关性[J].中国妇幼保健,2021,36(3):514-517.
[15] 张宝玉,冯英梅,王旭红,等.人血管生成素样蛋白3与糖尿病血管病变和血脂紊乱相关性研究[J].临床医药实践,2022,23(8):565-568.
[16] 李金英,马晓娟.妊娠期糖尿病发生的危险因素分析及对妊娠结局的影响[J].解放军医药杂志,2020,32(2):67-70.
[17] 付威,李青菊,李俊,等.动态血糖监测及葡萄糖目标范围内时间对妊娠期糖尿病患者妊娠结局的影响研究[J].中国全科医学,2021,24(33):4251-4254,4260.
[18] 何金花,秦朦,王晨,等.探析25-羟基维生素D3与2型糖尿病肾病患者尿Netrin-1,Angptl4水平及肾功能的相关性[J].临床和实验医学杂志,2022,21(12):1266-1269.
[19] 代红沙,王新莉,赵春云.前列地尔联合诺和锐30及瑞舒伐他汀对糖尿病下肢血管病变患者糖脂代谢及ANGPTL4,hs-CRP水平的影响[J].河北医药,2021, 43(3):376-379.
[20] 盛莉,王琳,何周桃,等.血清肌肉生长抑素,多配体蛋白聚糖-1对酒精性肝硬化患者肝癌发生风险及其预后评估价值[J].创伤与急危重病医学,2021,9(4):253-256,261.